Skip to content Skip to footer
Subscribe Now
Takeda at AASLD 2024: Chinwe Ukomadu in a Riveting Dialogue Exchange with PharmaShots
VIEWPOINTS

Takeda at AASLD 2024: Chinwe Ukomadu in a Riveting Dialogue Exchange with PharmaShots

Shots:   AATD-associated liver disease is a progressive genetic disorder with no approved therapy, and liver transplantation remains the only option for patients with end-stage disease.  Fazirsiran is an investigational RNAi therapy designed to treat AATD-associated liver disease by lowering the production of Z-AAT.  PharmaShots welcomes Dr. Chinwe Ukomadu, Head of the Gastrointestinal and Inflammation Therapeutic…
May 5, 2025

Read more

Spotlight_Barbara Albientz
SPOTLIGHT

Reuters Pharma 2025: Post-Conference Talks Featuring Barbara Albientz

Barbara Albientz, Chief Commercialization Officer, Helvion Pharmaceuticals, joins PharmaShots’ Managing Editor Himanshu Sehgal for a riveting dialogue exchange. Barbara shares her experience from the recently held Reuters Events Pharma 2025, where she joined as an affirmative team member for the debate Reality Check: Is Omnichannel Actually Working? Barbara believes AI will be crucial in segmenting…
May 1, 2025

Read more

Insight+_Ridhi Rastogi
INSIGHTS+

New Drug Designations – March 2025 

Shots:      PharmaShots’ Designation Report provides a concise overview of the latest drug designations granted by major regulatory authorities, including the FDA, EMA, MHLW, and NMPA    The March 2025 report covers designations granted to 37 drugs and 3 medical devices, spanning 11 small molecules, 10 biologics, 10 cell and gene therapies & 3 medical devices among…
April 29, 2025

Read more

Spotlight_Jayasree Iyer
SPOTLIGHT

Reuters Pharma 2025: Post Conference Talks Featuring Jayasree K. Iyer 

Jayasree K. Iyer, CEO of Access to Medicine Foundation, moderated a panel discussion that featured leaders from the 2024 Access to Medicine Index. Jayasree highlighted how biopharma companies foster accessibility to essential medicines in low- and middle-income countries through global partnerships, innovation, and sustainable models. Jayasree talks about the future of Health Equity amidst the…
April 29, 2025

Read more

Viewpoints_Jesse Mendelsohn
VIEWPOINTS

Predicting 2025 Trends: Jesse Mendelsohn from Model N in an Illuminating Discussion with PharmaShots

Shots:  Several undulating factors coalesce to inadvertently shape the biopharma industry  Prominent challenges include mounting pressure on Pharmacy Benefit Managers from independent pharmacies and drug manufacturers, a growing shortage of GLP-1 drugs, and the addition of 15 more drugs to the Inflation Reduction Act’s price negotiation list.  Jesse Mendelsohn, SVP at Model N, emphasizes the…
April 28, 2025

Read more

Thoughtspot_Saurabh_Chaubey
THOUGHTSPOT

Personalized Medicine: A Paradigm Shift in Modern Treatment Approach

Shots:   Precision medicine holds a promising foothold in addressing unmet healthcare needs and bridging the gaps in care accessibility and high treatment costs  Defying the one-size-fits-all model, personalized medicine offers therapies tailored to an individual’s physiology, lifestyle, and environment  With this article, let’s capture the intricacies of precision medicine by navigating the benefits, challenges, progress,…
April 23, 2025

Read more

Insights+: The US FDA New Drug Approvals in August 2023
INSIGHTS+

The US FDA New Drug Approvals in March 2025

Shots:      PharmaShots has compiled a list of US FDA-approved drugs in the month of March 2025       The US FDA has approved a total of 2 new drug including 2 new molecular entities leading to the treatment of patients and advances in the healthcare industry        The major highlighted drug was GSK’s Blujepa securing approval for treating…
April 15, 2025

Read more

Load more